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The use of ‘real-time’ complement analysis to differentiate
atypical haemolytic uraemic syndrome from other forms of
thrombotic microangiopathies
We read with great interest the recent correspondence of Dr
Cataland and colleagues (Cataland et al, 2012), who appro-
priately pointed out that symptoms alone cannot differentiate
thrombotic thrombocytopenic purpura (TTP) from atypical
haemolytic uraemic syndrome (aHUS) in patients with
thrombotic microangiopathies (TMAs). The data presented
(Cataland et al, 2012) indicated that alternative diagnoses to
TTP, including aHUS, should be considered in TMA patients
with non-deficient ADAMTS13 activity (>10%), moderate
thrombocytopenia (>30 9 109/l), pronounced abnormalities
of renal function, and suboptimal response to plasma
exchange (PEX) (absence of a steadily declining lactate dehy-
drogenase level and an increase in the platelet count after 4–
5 d of daily PEX). Cataland et al (2012) concluded that, in
the absence of an objective test to reliably diagnose aHUS,
the combination of the above laboratory and clinical
response data should help clinicians to identify patients who
may benefit from therapy with the complement-inhibiting
drug, eculizumab.
The clinical data-based objective criteria, as described by
Cataland et al (2012), seems to be valid and highly practical,
however, based on our latest diagnostic experiences, we
would like to suggest the use of additional, parallel ‘real-
time’ complement testing in this setting. Given that ongoing
pathological activation and consumption of the alternative
complement pathway is the core factor in the pathophysiol-
ogy of aHUS (Noris & Remuzzi, 2009), we hypothesized that
functional testing of the alternative pathway and measure-
ment of the alternative pathway components C3 and factor
B, may provide valuable diagnostic information in patients
with acute aHUS, and differentiate them from patients with
other forms of TMA.
Samples from 55 patients with an acute TMA episode
[defined as microangiopathic haemolytic anaemia and
thrombocytopenia (<130 9 109/l)] were consecutively
referred to our research laboratory between April 2008 and
February 2012, and parallel testing of ADAMTS13 activity
and complement parameters were performed for all patients
according to current guidelines (Ariceta et al, 2009; Taylor
et al, 2010; Loirat & Fremeaux-Bacchi, 2011; Roumenina
et al, 2011). Functional assessment of the alternative pathway
was done with the Wieslab® (Euro Diagnostica, Malmö, Swe-
den) alternative pathway enzyme linked immunosorbent
assay kit (Seelen et al, 2005), C3 was measured by immuno-
turbidimetry and factor B by radial immune diffusion.
Demographic and laboratory data are presented in aggregate
for patients with final diagnosis of aHUS, TTP and typical
(D+)HUS in Table I. The following criteria were used to
establish the final diagnosis (Besbas et al, 2006; Scheiring
et al, 2010): aHUS: acute renal failure, lack of bloody diar-
rhoea, non-deficient ADAMTS13 activity (>7%) and presence
of complement genetic abnormalities (four cases with com-
plement-factor H-related protein 1 deficiency with anti-factor
H autoantibodies, two cases with complement factor H
mutations, one case with membrane cofactor protein muta-
tion, two recent cases with ongoing sequencing); TTP: pres-
ence of ADAMTS13 deficiency with ADAMTS13 inhibitors,
no concomitant disease; D+HUS: sudden onset with typical






















aHUS, n = 9 7 (0–20) 4 (44) 44 (27–80) 9 (100) 9 (100) 7 (78) 7 (78)
TTP, n = 34 41 (13–71) 30 (88) 0 (0–3) 2 (6) 4 (12) 5 (15) 1 (3)
D+HUS, n = 12 18 (1–68) 8 (67) 66 (56–76) 1 (8) 3 (25) 1 (8) 0 (0)
P-value <0·0001 0·015 <0·0001 <0·0001 <0·0001 0·0005 <0·0001
aHUS, atypical haemolytic uremic syndrome; TTP, thrombotic thrombocytopenic purpura; D+HUS, diarrhoea-associated HUS; reference ranges:
complement C3 0·9–1·8 g/l, alternative pathway activity 70–105%, complement factor B antigen 70–130%, ADAMTS13 67–151%.
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signs of gastroenteritis with diarrhoea, lack of ADAMTS13
deficiency, good clinical response to supportive therapy and
no long-term renal complication or disease recurrence (med-
ian follow up 11 months).
We observed low (<70%) total alternative pathway activity
and decreased C3 levels (<0·9 g/l) in 100% of acute aHUS
cases, whereas low (<70%) factor B concentrations were pres-
ent in seven out of the nine aHUS cases (78%). All of the
three complement results were decreased in 78% of aHUS
cases (Table I). However, decreased complement parameters
were very infrequent in TTP and D+HUS; only one TTP
patient had three decreased complement results. The positive
predictive value of having all the three complement parame-
ters decreased (aHUS versus TTP plus D+HUS) was 0·875,
whereas not having all of them decreased carried a negative
predictive value of 0·957. Based on these results, we consid-
ered testing of the complement alternative pathway useful for
differentiating aHUS cases from other forms of TMA unre-
lated to secondary causes (including sepsis and disseminated
intravascular coagulation, systemic autoimmune diseases,
malignancies, transplantation).
The major limitation of the utilization of complement
tests in this urgent clinical setting is their restricted availabil-
ity. There are only a few laboratories worldwide providing
complement alternative pathway testing for diagnostic pur-
poses (see Ariceta et al, 2009), thus, it is an important imme-
diate task to increase availability of these tests in local
immunological/haematological laboratories. However, in the
case of our 55 acute TMA patients, the average turnaround
time (including transportation from other cities or countries)
until functional testing of the alternative pathway, measuring
C3, factor B and ADAMTS13 activity, was 3–5 working days.
Our laboratory treats these tests as urgent for patients with
acute TMA, if notified prior to sample shipping (ADAMTS13
and alternative pathway activity testing with C3 is performed
within 1 working day).
The time interval of 3–5 d for complement testing fits clo-
sely to the proposal of Cataland et al (2012): the initial
investigations for concomitant diseases and judgment of
response to PEX in TMA patients may also take 4–5 d. Thus,
if complement and ADAMTS13 investigations are initiated at
the earliest available time-point (preferably before the initia-
tion of PEX, although prior plasma therapy does not make
testing impossible), the decision whether PEX should be
stopped or continued, with or without alternative treatment
(B-cell inhibition with rituximab or complement inhibition
with eculizumab) can be made based on the results of suffi-
ciently specific laboratory tests with good positive- and nega-
tive-predictive values.
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